Efficacy of Combination of Insulin Glargine with either Metformin or Sulfonylurea in Patients with Poorly Controlled Type 2 Diabetes

被引:2
作者
Chuang, Shih-Ming [1 ,2 ]
Wang, Chao-Hung [1 ]
Liu, Sung-Chen [1 ,3 ]
Chien, Ming-Nan [1 ,3 ]
Chen, Wei-Che [1 ,3 ]
机构
[1] Mackay Mem Hosp, Dept Internal Med, Div Endocrinol & Metab, Taipei, Taiwan
[2] Mackay Jr Coll Med Nursing & Management, Taipei, Taiwan
[3] Mackay Med Coll, Dept Med, New Taipei, Taiwan
关键词
type; 2; diabetes; insulin glargine; sulfonylurea; metformin; TO-TARGET TRIAL; GLUCOSE-LOWERING DRUGS; GLYCEMIC CONTROL; BASAL INSULIN; ORAL-THERAPY; NAIVE PEOPLE; NPH INSULIN; LIFE-STYLE; ADD-ON; MELLITUS;
D O I
10.6890/IJGE.202005_14(2).0010
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Background: Although adding insulin glargine to oral antidiabetic drugs (OADs) has demonstrated efficacy in patients with type 2 diabetes, evidence supporting specific regimens is lacking. The aim of this study was to compare the efficacy of combination therapy of insulin glargine with either sulfonylurea (SU) or metformin (Met) in patients with poorly controlled type 2 diabetes receiving >= 2 OADs. Methods: This was a 48-week prospective, open-label, randomized, parallel trial. Patients with type 2 diabetes poorly controlled with >= 2 OADs were randomized to the insulin glargine with Met (Met-group) or insulin glargine with SU (SU-group). Results: Mean glycosylated hemoglobin (A1C) reduction were significant in the Met-group and SU-group (-1.42 +/- 0.28% and -1.00 +/- 0.28%, respectively), but no statistically significant difference between groups (-0.40 +/- 0.3%, p = 0.234). There was no difference in the proportion of patients achieving A1C of < 7% (12.8% and 6.8%, respectively). Mean FPG reduced significantly in both groups (-120.3 +/- 8.8 mg/dL and -90.2 +/- 11.1 mg/dL, respectively), with greater reductions in the Met-group (-34.8 +/- 10.0 mg/dL, p< 0.001). More proportions of patients in the Met-group achieved the FPG target of < 130 mg/dL (80.9% and 40.9%, respectively, p < 0.001). The percentages of patients experiencing episodes of symptomatic hypoglycemia (Met-group: 23.4%, SU-group: 19.6%) and the percentages of nocturnal hypoglycemia (Met-group: 8.5%, SU-group: 6.5%) were similar among the two groups. Conclusion: In patients with type 2 diabetes poorly controlled on >= 2 OADs, glycemic control was comparable among the two regimens. Copyright (C) 2020, Taiwan Society of Geriatric Emergency & Critical Care Medicine.
引用
收藏
页码:138 / 141
页数:4
相关论文
共 22 条
[2]   Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATETM study [J].
Blonde, L. ;
Merilainen, M. ;
Karwe, V. ;
Raskin, P. .
DIABETES OBESITY & METABOLISM, 2009, 11 (06) :623-631
[3]   Blood Glucose Management of Type 2 Diabetes in the Older People [J].
Chen, Wei-Che ;
Lee, Chun-Chua ;
Chien, Ming-Nan ;
Liu, Sung-Chen ;
Wang, Chao-Hung ;
Yang, Wei-Shiung .
INTERNATIONAL JOURNAL OF GERONTOLOGY, 2018, 12 (03) :170-174
[4]   Improvement of glycemic control in subjects with poorly controlled type 2 diabetes - Comparison of two treatment algorithms using insulin glargine [J].
Davies, M ;
Storms, F ;
Shutler, S ;
Bianchi-Biscay, M ;
Gomis, R .
DIABETES CARE, 2005, 28 (06) :1282-1288
[5]   Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes -: A randomized, controlled trial [J].
Fritsche, A ;
Schweitzer, MA ;
Häring, HU .
ANNALS OF INTERNAL MEDICINE, 2003, 138 (12) :952-959
[6]   CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM-2016 EXECUTIVE SUMMARY [J].
Garber, Alan J. ;
Abrahamson, Martin J. ;
Barzilay, Joshua I. ;
Blonde, Lawrence ;
Bloomgarden, Zachary T. ;
Bush, Michael A. ;
Dagogo-Jack, Samuel ;
DeFronzo, Ralph A. ;
Einhorn, Daniel ;
Fonseca, Vivian A. ;
Garber, Jeffrey R. ;
Garvey, W. Timothy ;
Grunberger, George ;
Handelsman, Yehuda ;
Henry, Robert R. ;
Hirsch, Irl B. ;
Jellinger, Paul S. ;
McGill, Janet B. ;
Mechanick, Jeffrey I. ;
Rosenblit, Paul D. ;
Umpierrez, Guillermo E. .
ENDOCRINE PRACTICE, 2016, 22 (01) :84-102
[7]   A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes [J].
Hermansen, Kjeld ;
Davies, Melanie ;
Derezinski, Taudeusz ;
Ravn, Gabrielle Martinez ;
Clauson, Per ;
Home, Philip .
DIABETES CARE, 2006, 29 (06) :1269-1274
[8]   Use of Insulin Glargine 100U/mL for the Treatment of Type 2 Diabetes Mellitus in East Asians: A Review [J].
Hirose, Takahisa ;
Chen, Ching-Chu ;
Ahn, Kyu Jeung ;
Kiljanski, Jacek .
DIABETES THERAPY, 2019, 10 (03) :805-833
[9]   10-year follow-up of intensive glucose control in type 2 diabetes [J].
Holman, Rury R. ;
Paul, Sanjoy K. ;
Bethel, M. Angelyn ;
Matthews, David R. ;
Neil, H. Andrew W. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (15) :1577-1589
[10]   Predictors for achieving target glycemic control in Japanese patients with type 2 diabetes after initiation of basal supported oral therapy using insulin glargine: sub-analysis of the ALOHA2 study, drug use surveillance in Japan [J].
Ikeda Y. ;
Tsukube S. ;
Kadowaki T. ;
Odawara M. .
Diabetology International, 2016, 7 (2) :188-198